The DOI matches its Crossref record; 279 of the 282 references it cites were found in a registry or an index.
High-density lipoproteins: A consensus statement from the National Lipid Association
Abstract
For >4 decades it has been recognized that elevated serum levels of high-density lipoprotein cholesterol (HDL-C) are associated with reduced risk of cardiovascular disease (CVD) and its sequelae. Many prospective observational studies performed around the world have confirmed an inverse relationship between HDL-C and cardiovascular risk in people irrespective of sex, race, or ethnicity. Consequently, it was assumed that, by extension, raising HDL-C through lifestyle modification and pharmacologic intervention would reduce risk of CVD. Animal studies are consistent with this assumption. Lipid treatment guidelines around the world promoted the recognition of HDL-C as a therapeutic target, especially in high-risk patients. Some post hoc analyses from randomized controlled trials also suggest that raising HDL-C beneficially affects the risk of CVD. However, a number of recent randomized studies putatively designed to test the "HDL hypothesis" have failed to show benefit. The results of these trials have caused many clinicians to question whether HDL-C is a legitimate therapeutic target. In response to the many questions and uncertainties raised by the results of these trials, the National Lipid Association convened an expert panel to evaluate the current status of HDL-C as a therapeutic target; to review the current state of knowledge of HDL particle structure, composition, and function; and to identify the salient questions yet to be answered about the role of HDL in either preventing or contributing to atherosclerotic disease. The expert panel's conclusions and clinical recommendations are summarized herein. The panel concludes that, although low HDL-C identifies patients at elevated risk, and much investigation suggests that HDL may play a variety of antiatherogenic roles, HDL-C is not a therapeutic target at the present time. Risk stratified atherogenic lipoprotein burden (low-density lipoprotein cholesterol and non-HDL-C) should remain the primary and secondary targets of therapy in patients at risk, as described by established guidelines. The National Lipid Association emphasizes that rigorous research into the biology and clinical significance of low HDL-C should continue. The development of novel drugs designed to modulate the serum levels and functionality of HDL particles should also continue. On the basis of an enormous amount of basic scientific and clinical investigation, a considerable number of reasons support the need to continue to investigate the therapeutic effect of modulating HDL structure and function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HDL-C is well known to play an anti-atherosclerotic role by protecting against the development of CVD; indeed, increased serum concentrations of HDL-C are strongly inversely related to the risk of atherosclerotic CVD [6,7].”
In the citing paper
“High-density lipoprotein cholesterol (HDL-C) is a strong, consistent, and independent predictor of cardiovascular events”
From Effects of aerobic exercise on lipids and lipoproteins (2017) · cites this paper as [2]
In the citing paper
“This is biologically plausible since HDL particles drive reverse cholesterol transport and may exert a variety of anti-atherogenic effects3.”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [3]
In the citing paper
“For many decades, a low level of HDL-C has been viewed as a robust and independent CVD risk factor1-4.”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [3]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,737
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Self-citationGrundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“This possibility was further supported in the primary prevention Helsinki Heart Study (HHS) in which a 1% increase in HDL-C with gemfibrozil was associated with a 3% decrease in CVD events.(34) Another randomized controlled trial that tested the fibric acid gemfibrozil was the Veterans Affairs HDL Intervention Trial (…”
ResultBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“By contrast, fenofibrate failed to show CHD benefits in recent trials conducted in diabetic participants in whom most were without overt dyslipidemia (Fenofibrate Intervention and Event Lowering in Diabetes and Action to Control Cardiovascular Risk in Diabetes).(107,108) Post hoc analyses of all these trials (HHS, Bez…”
ResultMicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,396
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationBrown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Dawber, T. R. (1980) · Harvard University Press eBooks · doi:10.4159/harvard.9780674492097 · Cited by 1,965
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Self-citationFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Presentation of multivariate data for clinical use: The Framingham Study risk score functions
SULLIVAN, L. M., Massaro, J. M., & D’Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1742 · Cited by 1,756
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547 · cited 1×
“Clinical and epidemiologic studies show a robust, inverse association of HDL-C level with CVD risk.(250,251) Moreover, hypercholesterolemic mice with genetically engineered deficiencies in proteins implicated in HDL metabolism have strongly atherosclerotic phenotypes,(252) providing compelling evidence that HDL is a k…”
BackgroundAntiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394
Self-citationRidker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation · doi:10.1161/circulationaha.105.548206 · Cited by 1,298 · cited 1×
“65% of diabetes-related deaths due to late-stage effects of cardiac or blood vessel disease.(102,104) These numbers are expected to increase in the next 10 years, because of the alarming rise in obesity across the globe.”
BackgroundSelf-citationEpidemiology of coronary heart disease: the Framingham study.
Castelli, W. (1984) · American Journal of Medicine · doi:10.1016/0002-9343(84)90952-5 · Cited by 1,106
Ervin, R. B. (2009) · PubMed · Cited by 1,000
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., & Clift, S. (1991) · Nature · doi:10.1038/353265a0 · Cited by 985
Self-citationCholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
Self-citationVaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Self-citationArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men
Rhoads, G. G., Gulbrandsen, C. L., & Kagan, A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602052940601 · Cited by 876
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 862
Lenten, B. J. V., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., Du, B. N. L., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118345 · Cited by 839
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Badimón, J. J., Badimón, L., & Fuster, V. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114558 · Cited by 764
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Self-citationLipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 734
Navab, M., Imes, S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., & Laks, H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115532 · Cited by 733
Tardif, J. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 725
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., Wolinska, I., Lipinski, K. V. W., Baba, H. A., Tietge, U. J. F., Gödecke, A., Ishii, I., Kleuser, B., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18004 · Cited by 705
Navab, M., Ananthramaiah, G. M., Reddy, S. T., Lenten, B. J. V., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S. Y., Hough, G., Kamranpour, N., et al. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400001-jlr200 · Cited by 703
Assmann, G., Schulte, H., von Eckardstein, A., & Huang, Y. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05852-2 · Cited by 700
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685
Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses
Yvan‐Charvet, L., Wang, N., & Tall, A. R. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179283 · Cited by 683
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 663
Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 647
Self-citationHigh density lipoprotein cholesterol and mortality. The Framingham Heart Study.
Wilson, P. W. F., Abbott, R. D., & Castelli, W. P. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.6.737 · Cited by 644
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Self-citationEndothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnström, J., Sevvana, M., Egerer-Sieber, C., Muller, Y. A., Hla, T., Nielsen, L. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103187108 · Cited by 617
Characterization of human high-density lipoproteins by gradient gel electrophoresis
Blanche, P. J., Gong, E. L., Forte, T. M., & Nichols, A. V. (1981) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(81)90253-8 · Cited by 614
Molecular regulation of HDL metabolism and function: implications for novel therapies
Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 610
Self-citationHDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J., van der Giet, M., Tölle, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418004 · Cited by 607
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis
Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J. T., & Rothblat, G. H. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800088-jlr200 · Cited by 597
Self-citationIschemic Heart Disease, Atherosclerosis, and Longevity
Gofman, J. W., Young, W., & Tandy, R. K. (1966) · Circulation · doi:10.1161/01.cir.34.4.679 · Cited by 587
Plump, A. S., Scott, C., & Breslow, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9607 · Cited by 569
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Chapman, M. J., Goldstein, S., Lagrange, D., & Laplaud, P. M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35376-1 · Cited by 553
Self-citationScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., & Shinkai, H. (2000) · Nature · doi:10.1038/35018119 · Cited by 532
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 523
Self-citationThompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
Cashin-Hemphill, L. (1990) · JAMA · doi:10.1001/jama.264.23.3013 · Cited by 493
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Self-citationBowry, V. W., Stanley, K. K., & Stocker, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10316 · Cited by 479
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress
Kontush, A., Chantepie, S., & Chapman, M. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000091338.93223.e8 · Cited by 452
Self-citationHigh-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men
Spieker, L. E., Sudano, I., Hürlimann, D., Lerch, P. G., Lang, M. G., Binggeli, C., Corti, R., Ruschitzka, F. T., Lüscher, T. F., & Noll, G. (2002) · Circulation · doi:10.1161/01.cir.0000013424.28206.8f · Cited by 437
Abbott, R. D., Wilson, P. W. F., Kannel, W. B., & Castelli, W. P. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.3.207 · Cited by 436
Zhang, Y., Zanotti, I., Reilly, M. P., Glick, J. M., Rothblat, G. H., & Rader, D. J. (2003) · Circulation · doi:10.1161/01.cir.0000086981.09834.e0 · Cited by 435
Self-citationDavidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.186031 · Cited by 415
Self-citationNicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Isolated Low HDL Cholesterol As a Risk Factor for Coronary Heart Disease Mortality
Goldbourt, U., Yaari, S., & Medalie, J. H. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.1.107 · Cited by 390
Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo
Naik, S. U., Wang, X., Silva, D., Jaye, M., Macphee, C. H., Reilly, M. P., Billheimer, J. T., Rothblat, G. H., & Rader, D. J. (2005) · Circulation · doi:10.1161/circulationaha.105.560177 · Cited by 388
Self-citationde la Llera-Moya, M., Drazul‐Schrader, D., Asztalos, B. F., Cuchel, M., Rader, D. J., & Rothblat, G. H. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.199158 · Cited by 385
Self-citationHigh density lipoproteins and coronary heart disease
Barter, P. J., & Rye, K.-A. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05675-0 · Cited by 377
Self-citationCastelli, W., & Anderson, K. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90157-9 · Cited by 374
Mackey, R. H., Greenland, P., Goff, D. C., Lloyd‐Jones, D. M., Sibley, C. T., & Mora, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.060 · Cited by 371
Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., & Liebisch, G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.d800028-jlr200 · Cited by 369
SHAH, A. S., Tan, L., Long, J. L., & Davidson, W. S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035725 · Cited by 359
Self-citationSata, T., Havel, R. J., & Jones, A. L. (1972) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39346-9 · Cited by 359
Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.
Otvos, J. D. (2002) · PubMed · Cited by 347
High-density lipoprotein heterogeneity and function in reverse cholesterol transport
Rothblat, G. H., & Phillips, M. C. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338472d · Cited by 341
Genest, J. J., McNamara, J. R., Ordovás, J. M., Jenner, J. L., Silberman, S. R., Anderson, K. M., Wilson, P. W. F., Salem, D. N., & Schaefer, E. J. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90520-w · Cited by 333
The roles of different pathways in the release of cholesterol from macrophages
Adorni, M. P., Zimetti, F., Billheimer, J. T., Wang, N., Rader, D. J., Phillips, M. C., & Rothblat, G. H. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700274-jlr200 · Cited by 332
Self-citationThe metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Self-citationGenetic Variant of the Scavenger Receptor BI in Humans
Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317
Yancey, P. G., de la Llera-Moya, M., Swarnakar, S., Monzo, P., Klein, S. M., Connelly, M. A., Johnson, W. J., Williams, D. L., & Rothblat, G. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006924200 · Cited by 312
Rittershaus, C. W., MILLER, D. P., Thomas, L. J., Picard, M. D., Honan, C. M., Emmett, C. D., Pettey, C. L., Adari, H. Y., Hammond, R. A., Beattie, D. T., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2106 · Cited by 308
Taylor, A. J., Lee, H. J., & Sullenberger, L. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148508 · Cited by 303
Lipid composition of human serum lipoproteins
Skipski, V. P., Barclay, M., Barclay, R. K., Fetzer, V., Good, J., & Archibald, F. M. (1967) · Biochemical Journal · doi:10.1042/bj1040340 · Cited by 303
Schwartz, C. C., Halloran, P. F., Vlahčevič, Z. R., Gregory, D. H., & Swell, L. (1978) · Science · doi:10.1126/science.204996 · Cited by 300
Asztalos, B. F., Cupples, L. A., Demissie, S., Horvath, K. V., Cox, C. E., Batista, M. C., & Schaefer, E. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000146325.93749.a8 · Cited by 298
Gordon, D. J., Knoke, J. D., Probstfield, J. L., Superko, H. R., & Tyroler, H. A. (1986) · Circulation · doi:10.1161/01.cir.74.6.1217 · Cited by 289
HDL Cholesterol Predicts Coronary Heart Disease Mortality in Older Persons
Corti, M.-C. (1995) · JAMA · doi:10.1001/jama.1995.03530070037026 · Cited by 284
High density lipoprotein distribution
Anderson, D. W., Nichols, A. V., Pan, S., & Lindgren, F. T. (1978) · Atherosclerosis · doi:10.1016/0021-9150(78)90005-9 · Cited by 283
Oxidation of High Density Lipoproteins
Garner, B., Witting, P. K., Waldeck, A. R., Christison, J. K., Raftery, M. J., & Stocker, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6080 · Cited by 278
Hirano, K.-I., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., & Matsuzawa, Y. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1053 · Cited by 275
Uremia Alters HDL Composition and Function
Holzer, M., Birner‐Gruenberger, R., Stojaković, T., El‐Gamal, D., Binder, V., Wadsack, C., Heinemann, Á., & Marsche, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111144 · Cited by 273
Goldbourt, U., & Medalie, J. H. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112683 · Cited by 271
Asztalos, B. F., Collins, D., Cupples, L. A., Demissie, S., Horvath, K. V., Bloomfield, H. E., Robins, S. J., & Schaefer, E. J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000183727.90611.4f · Cited by 268
Zhang, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25327 · Cited by 267
Johansson, J., Carlson, L. A., Landou, C., & Hamsten, A. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.174 · Cited by 259
Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans
Schwartz, C. C., VandenBroek, J. M., & Cooper, P. S. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300511-jlr200 · Cited by 250
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246
Absorption and lipoprotein transport of sphingomyelin
Nilsson, Å., & Duan, R. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500357-jlr200 · Cited by 246
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Gordon, S. M., Deng, J., Lu, L. J., & Davidson, W. S. (2010) · Journal of Proteome Research · doi:10.1021/pr100520x · Cited by 243
Self-citationPrevalence of risk factors in men with premature coronary artery disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90924-a · Cited by 243
Karlsson, H., Leanderson, P., Tagesson, C., & Lindahl, M. G. (2005) · PROTEOMICS · doi:10.1002/pmic.200401010 · Cited by 242
High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease
Kannel, W. B. (1983) · The American Journal of Cardiology · doi:10.1016/0002-9149(83)90649-5 · Cited by 242 · cited 2×
“The atherogenic component of serum total-C derives from the LDL-C fraction, and the HDL-C component was shown to be inversely related to the development of CHD.39,40 Although the strength of the relation of total-C to CHD declines after 60 years of age in men, the totalC/HDL-C ratio continues to predict events reliabl…”
BackgroundReaven, G. M. (1994) · PubMed · Cited by 241
Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., & Mizushima, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5033 · Cited by 241
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 239
Prevalence of High Blood Cholesterol Among US Adults
Sempos, C. T. (1993) · JAMA · doi:10.1001/jama.1993.03500230091035 · Cited by 239
Distribution of lipids in 8,500 men with coronary artery disease
Bloomfield, H. E., Robins, S. J., Collins, D. E., Iranmanesh, A., Wilt, T. J., Mann, D. L., Mayo‐Smith, M. F., Faas, F. H., Elam, M. B., Rutan, G. H., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80761-9 · Cited by 238
Novel Biological Functions of High-Density Lipoprotein Cholesterol
Mineo, C., & Shaul, P. W. (2012) · Circulation Research · doi:10.1161/circresaha.111.258673 · Cited by 237
Asztalos, B. F., Sloop, C. H., Wong, L., & Roheim, P. S. (1993) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(93)90253-6 · Cited by 235
Regulation and mechanisms of macrophage cholesterol efflux
Tall, A. R., Costet, P., & Wang, N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16391 · Cited by 235
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
High-Density Lipoprotein Particle Size and Concentration and Coronary Risk
Harchaoui, K. E., Arsenault, B. J., Franssen, R., Després, J., Hovingh, G. K., Stroes, E. S. G., Otvos, J. D., Wareham, N. J., Kastelein, J. J. P., Khaw, K., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00006 · Cited by 231
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M. J., Björkhem, I., Angelin, B., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000161928.16334.dd · Cited by 230
Self-citationKontush, A., Thérond, P., Zerrad-Saadi, A., Couturier, M., Nègre‐Salvayre, A., Souza, J. A., Chantepie, S., & Chapman, M. J. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.145672 · Cited by 228
Self-citationStimulation of Fecal Steroid Excretion After Infusion of Recombinant Proapolipoprotein A-I
Eriksson, M., Carlson, L. A., Miettinen, T. A., & Angelin, B. (1999) · Circulation · doi:10.1161/01.cir.100.6.594 · Cited by 227
Canner, P. L., Furberg, C. D., Terrin, M. L., & McGovern, M. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.013 · Cited by 226
Direct Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis
Caulfield, M. P., Li, S., Lee, G. S., Blanche, P. J., Salameh, W. A., Benner, W. H., Reitz, R. E., & Krauss, R. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.100586 · Cited by 225
Self-citationDifferential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux
Asztalos, B. F., de la Llera-Moya, M., Dallal, G. E., Horvath, K. V., Schaefer, E. J., & Rothblat, G. H. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500187-jlr200 · Cited by 224
Waksman, R., Torguson, R., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., Martin, B. D., Perlman, T. J., Maltais, J. B., Weissman, N. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.067 · Cited by 224
Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.017 · Cited by 223
Self-citationCovey, S. D., Krieger, M., Wang, W., Penman, M., & Trigatti, B. L. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000083343.19940.a0 · Cited by 221
Gu, X.-J., Trigatti, B. L., Xu, S., Acton, S. L., Babitt, J. L., & Krieger, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26338 · Cited by 220
Multicompartmental Analysis of Cholesterol Metabolism in Man
Schwartz, C. C., Berman, M., Vlahcevic, Z. R., Halloran, P. F., Gregory, D. H., & Swell, L. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108952 · Cited by 218
Prevalence of Risk Factors in Men With Premature Coronary Artery Disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1992) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-199203010-00011 · Cited by 217
Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J., & Nissen, S. E. (2008) · Circulation · doi:10.1161/circulationaha.108.790733 · Cited by 214
Identification of the trypanocidal factor in normal human serum: high density lipoprotein.
Rifkin, M. R. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.7.3450 · Cited by 213
Parker, T. S., Levine, D. M., Chang, J. C., Laxer, J., Coffin, C. C., & Rubin, A. L. (1995) · Infection and Immunity · doi:10.1128/iai.63.1.253-258.1995 · Cited by 211
Bérard, A. M., Föger, B., Remaley, A. T., Shamburek, R. D., Vaisman, B. L., Talley, G. D., Paigen, B. J., Hoyt, R. F., Marcovina, S. M., Brewer, H. B., et al. (1997) · Nature Medicine · doi:10.1038/nm0797-744 · Cited by 209
Kwon, Y.-G., Min, J., Kim, K. M., Lee, D.-J., Billiar, T. R., & Kim, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011449200 · Cited by 206
Familial hyper-alpha-lipoproteinemia: Studies in eighteen kindreds
Glueck, C. J., Fallat, R. W., Millett, F., Gartside, P. S., Elston, R. C., & Go, R. C. P. (1975) · Metabolism · doi:10.1016/0026-0495(75)90063-3 · Cited by 205
Larrède, S., Quinn, C. M., Jessup, W., Frisdal, É., Olivier, M., Hsieh, V., Kim, M., Eck, M. V., Couvert, P., Carrié, A., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.194548 · Cited by 202
Self-citationPolymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction
Ridker, P. M., Paré, G., Parker, A. N., Zee, R. Y. L., Miletich, J. P., & Chasman, D. I. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.817304 · Cited by 202
Serum Amyloid A in Uremic HDL Promotes Inflammation
Weichhart, T., Kopecky, C., Kubicek, M., Haidinger, M., Döller, D., Katholnig, K., Suarna, C., Eller, P., Tölle, M., Gerner, C., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070668 · Cited by 201
Yvan‐Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T. T., Rinninger, F., Jiang, X., Shear, C. L., & Tall, A. R. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.138347 · Cited by 200
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
The HDL proteome in acute coronary syndromes shifts to an inflammatory profile
Al-Waili, K., Bailey, D., Awan, Z. A., Bailey, S. D., Ruel, I. L., Hafiane, A., Krimbou, L., LaBoissière, S., & Genest, J. J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.013 · Cited by 198
Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux.
Banka, C. L., Yuan, T., de Beer, M. C., Kindy, M. S., Curtiss, L. K., & de Beer, F. C. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39863-1 · Cited by 197
Goulinet, S., & Chapman, M. J. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.4.786 · Cited by 193
Self-citationMyeloperoxidase: An Oxidative Pathway for Generating Dysfunctional High-Density Lipoprotein
Shao, B., Oda, M. N., Oram, J. F., & Heinecke, J. W. (2009) · Chemical Research in Toxicology · doi:10.1021/tx9003775 · Cited by 189
Self-citationAdvances in Internal Medicine.
STURGIS, C. C., Davenport, F. M., Davey, W. N., Hoobler, S. W., Fd, J., POLLARD, H. M., & Jm, S. (1962) · Annals of Internal Medicine · doi:10.7326/0003-4819-57-5-864_3 · Cited by 189
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Self-citationPsoriasis alters HDL composition and cholesterol efflux capacity
Holzer, M., Wolf, P., Ćurčić, S., Birner‐Gruenberger, R., Weger, W., Inzinger, M., El‐Gamal, D., Wadsack, C., Heinemann, Á., & Marsche, G. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m027367 · Cited by 175
Aim-High Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.007 · Cited by 174
High density lipoprotein: it's not just about lipid transport anymore
Gordon, S. M., Hofmann, S. M., Askew, D. S., & Davidson, W. S. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.10.001 · Cited by 174
Self-citationProteomic analysis of high‐density lipoprotein
Rezaee, F., Casetta, B., Levels, J. H. M., Speijer, D., & Meijers, J. C. M. (2006) · PROTEOMICS · doi:10.1002/pmic.200500191 · Cited by 174
Morehouse, L. A., Sugarman, E. D., Bourassa, P.-A. K., Sand, T. M., Zimetti, F., Gao, F., Rothblat, G. H., & Milici, A. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600332-jlr200 · Cited by 173
Moore, R. E., Navab, M., Millar, J. S., Zimetti, F., Hama, S. Y., Rothblat, G. H., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000185320.82962.f7 · Cited by 173
Self-citationNicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A. J., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 172
Musunuru, K., Orho-Melander, M., Caulfield, M. P., Li, S., Salameh, W. A., Reitz, R. E., Berglund, G., Hedblad, B., Engström, G., Williams, P. T., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.190405 · Cited by 168
Self-citationWatanabe, J., Charles‐Schoeman, C., Miao, Y., Elashoff, D. A., Lee, Y. Y., Katselis, G. S., Lee, T. D., & Reddy, S. T. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34363 · Cited by 162
Gangliosides in normal human serum
Hans‐Jürgen, S. E. N. N., Orth, M., Fitzke, E., Wieland, H., & Gerok, W. (1989) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1989.tb14773.x · Cited by 160
Tölle, M., Pawlak, A., Schuchardt, M., Kawamura, A., Tietge, U. J. F., Lorkowski, S., Keul, P., Assmann, G., Chun, J. J. M., Levkau, B., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.161042 · Cited by 160
Pearson, T. A., Bulkley, B. H., Achuff, S. C., Kwiterovich, P. O., & Gordis, L. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112682 · Cited by 160
Zerrad-Saadi, A., Thérond, P., Chantepie, S., Couturier, M., Rye, K., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.194555 · Cited by 159
Self-citationCholesterol Profile Measurement by Vertical Auto Profile Method
Kulkarni, K. R. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.004 · Cited by 158
Davidson, W. S., Gillotte, K. L., Lund‐Katz, S., Johnson, W. J., Rothblat, G. H., & Phillips, M. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5882 · Cited by 158
Self-citationNicholls, S. J., Cutri, B., Worthley, S. G., Kee, P. H., Rye, K.-A., Bao, S., & Barter, P. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000184760.95957.d6 · Cited by 156
Self-citationIs There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter, P. J., & Rye, K. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.148817 · Cited by 151
Self-citationCholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Barter, P. J., & Rye, K.-A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024075 · Cited by 148
Self-citationLipoproteins inhibit macrophage activation by lipoteichoic acid
Grünfeld, C., Marshall, M. K., Shigenaga, J. K., Moser, A. H., Tobias, P. S., & Feingold, K. R. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33363-0 · Cited by 143
Jensen, M. K., Rimm, E. B., Furtado, J. D., & Sacks, F. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000232 · Cited by 142
Change in α 1 HDL Concentration Predicts Progression in Coronary Artery Stenosis
Asztalos, B. F., Batista, M. C., Horvath, K. V., Cox, C. E., Dallal, G. E., Morse, J. S., Brown, G. B., & Schaefer, E. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000066133.32063.bb · Cited by 137
Transintestinal cholesterol efflux
van der Velde, A. E., Brufau, G., & Groen, A. K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283395e45 · Cited by 135
Yetukuri, L., Söderlund, S., Koivuniemi, A., Seppänen‐Laakso, T., Niemelä, P. S., Hyvönen, M., Taskinen, M., Vattulainen, I., Jauhiainen, M., & Orešič, M. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006494 · Cited by 134
Miller, M., Seidler, A., Kwiterovich, P. O., & Pearson, T. A. (1992) · Circulation · doi:10.1161/01.cir.86.4.1165 · Cited by 131
Self-citationCanner, P. L., Furberg, C. D., & McGovern, M. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.070 · Cited by 131
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S. M., Brunzell, J. D., Knopp, R. H., Zhao, X.-Q., & Heinecke, J. W. (2008) · Circulation · doi:10.1161/circulationaha.108.770669 · Cited by 131
Self-citationEfficacy of lipid profiles in prediction of coronary disease
Kannel, W. B., & Wilson, P. W. F. (1992) · American Heart Journal · doi:10.1016/0002-8703(92)90288-7 · Cited by 128
Litman, B. J., Lewis, E. N., & Levin, I. W. (1991) · Biochemistry · doi:10.1021/bi00216a001 · Cited by 128
Souza, J. A., Vindis, C., Nègre‐Salvayre, A., Rye, K., Couturier, M., Thérond, P., Chantepie, S., Salvayre, R., Chapman, M. J., & Kontush, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00713.x · Cited by 128
Self-citation
Research works printed but not linked: 3
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
- Morse, 2001, Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose, J Am Coll Cardiol, 37, 262A
- Kannel, 1992, Efficacy of lipid profiles in prediction of coronary disease, Am Heart J, 124, 768, 10.1016/0002-8703(92)90288-7 · DOI
Cited by
Sorted by citations
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
“In an effort to offload TG from remnant lipoproteins (VLDL 2+3 and IDL; RLPs), CETP is activated and promotes an exchange of TG out of RLPs and incorporates CE from HDL and LDL particles [213].”
BackgroundHDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Self-citationSoy and Health Update: Evaluation of the Clinical and Epidemiologic Literature
Messina, M. (2016) · Nutrients · doi:10.3390/nu8120754 · Cited by 537
Effects of aerobic exercise on lipids and lipoproteins
Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells
Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M. G., Thacker, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4292 · Cited by 428
Self-citation
Metadata
- Authors
- Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., Karas, R. H., Kontush, A., Krauss, R. M., Miller, M., & Rader, D. J.
- Affiliations
- CGH Medical Center (US)
- The Heart Research Institute (AU)
- Icahn School of Medicine at Mount Sinai (US)
- Albany Medical College (US)
- Inserm (FR)
- University of Pennsylvania (US)
- University of Chicago (US)
- University of Cincinnati (US)
- University of Washington (US)
- Tufts University (US)
- University of California, San Francisco (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Toth, Peter P.
- ORCID
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 7
- Issue
- 5
- Pages
- 484-525
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W2106601510
- Cited by
- 336
- References
- 282
- Citations by year
- 2026: 6 · 2025: 21 · 2024: 10 · 2023: 21 · 2022: 34 · 2021: 24 · 2020: 38 · 2019: 25 · 2018: 28 · 2017: 26 · 2016: 19 · 2015: 41 · 2014: 41 · 2013: 2
- FWCI
- 33.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of clinical lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL112625)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- HDL cholesterol, cardiovascular risk, atherosclerosis, LDL cholesterol, non-HDL cholesterol, risk stratification
- MeSH terms
- Animals, Cardiovascular Diseases, Humans, Lipoproteins, HDL, Risk Factors, Societies, Scientific, Consensus, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
